Welcome to our dedicated page for SMITH & NEPHEW PLC SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SMITH & NEPHEW PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SMITH & NEPHEW PLC's regulatory disclosures and financial reporting.
SMITH & NEPHEW PLC (SNN) reports equity incentive awards to Nate Folkert, President, Orthopaedics. On September 1, 2026, he received a performance share award over 117,933 ordinary shares under the Smith & Nephew Performance Share Plan 2026, calculated at a reference price of £11.0265 per share. These shares may vest on March 15, 2029, subject to performance conditions measured from January 1, 2026 to December 31, 2028, with the 117,933 shares representing maximum vesting.
On the same date he also received a restricted share award over 67,164 ordinary shares under the Smith & Nephew Restricted Share Plan 2024, also based on £11.0265 per share. These restricted shares vest in three equal annual tranches, subject to continued employment and satisfactory performance, and both awards include additional shares equivalent to dividends on vested shares.
SMITH & NEPHEW PLC (SNN) reports on its 2026 Directors’ Remuneration Policy and Performance Share Plan after shareholder approval at the May 6, 2026 AGM, where the relevant resolutions each received under 80% support. The company then conducted further consultation with investors and proxy advisers representing about 70% of its issued share capital between May 18 and July 27, 2026.
After considering limited additional feedback, the board decided to implement the Policy and the Performance Share Plan on the terms approved at the AGM. Under the Policy, on September 1, 2026 the Remuneration Committee granted CEO Deepak Nath a top-up Performance Share Plan award equal to 350% of salary (total 2026 PSP awards 650% of salary) and a top-up Restricted Share Plan award equal to 25% of salary (total 2026 restricted share awards 150% of salary), represented by share awards that may vest over 2027–2029 subject to performance and other conditions.
SMITH & NEPHEW PLC (SNN) reports its updated voting rights and share capital position as at 31 August 2026. The company has a total issued share capital of 877,738,166 ordinary shares of US20¢ each, which includes 40,321,038 ordinary shares held in treasury.
After excluding treasury shares, the company's issued share capital with voting rights consists of 837,417,128 ordinary shares, each carrying one vote. Shareholders are directed to use this voting-share figure as the denominator when assessing whether they must notify their holdings or changes in holdings under the FCA's Disclosure Guidance and Transparency Rules.
Smith & Nephew plc (SNN) reports a TR-1 notification of major holdings from a holder within the Bank of America group. As of the threshold date, this holder had 2.461592% of Smith & Nephew’s voting rights attached to shares and 0.427242% through financial instruments, for a total of 2.888834%, representing 24,191,594 voting rights. This total compares with a previously notified position of 3.172736%. Voting rights attached to shares are held via ISIN US83175M2052, and additional exposure is held through rights to recall and various cash-settled swaps and a put option with expiries between 2027 and 2030.
SMITH & NEPHEW PLC (SNN) reports that Chief Financial Officer John Rogers has resigned to take an external role in the US. He will leave his CFO position on 30 September 2026 and has stepped down from the Board with immediate effect, while continuing to work for the company until his departure date.
Pierre Palassian, currently Senior Vice President Finance and Group Controller, will serve as interim CFO while a search for a permanent successor is conducted. Rogers will be paid in line with the company’s Remuneration Policy with no severance payment; all outstanding awards under the Annual Incentive Plan, Performance Share Plan and Restricted Share Plan will be treated as for ordinary leavers and will lapse on 30 September 2026.
Smith+Nephew describes itself as a global medical technology business focused on tissue repair, regeneration and replacement, with 17,000 employees, operations in around 100 countries, and $6.2 billion of annual sales in 2025.
Smith & Nephew plc reported a transaction by a person discharging managerial responsibilities under the UK Market Abuse Regulation. On 17 August 2026, restricted share awards granted in 2024 under the Smith & Nephew Restricted Share Plan 2024 vested. Following vesting, a portion of the resulting ordinary shares of US$0.20 each was sold on the London Stock Exchange (XLON) solely to cover tax liabilities arising from the vesting. Chief Executive Officer Deepak Nath had a total of 47,105 shares involved at an average price of £10.898231 per share, of which 19,492 shares were sold to meet tax obligations and 27,613 shares were retained. The company states that the acquired amounts include dividend-equivalent shares on the vested awards.
Smith+Nephew reported first-half 2026 revenue of $3,097m, up 4.6% year-on-year, with underlying revenue growth of 2.3%. Operating profit rose to $448m and trading profit to $566m, an 8.1% increase, lifting the trading profit margin to 18.3%. Adjusted EPS (EPSA) grew 11.0% to 47.7¢, while basic EPS increased 6.2% to 35.6¢.
Growth was led by Sports Medicine & ENT (revenue up 10.2%) and Emerging Markets (up 14.8%), offset by softer Orthopaedics (1.7% growth) and declines in Advanced Wound Bioactives driven by US reimbursement changes and a weaker quarter for SANTYL. The group delivered $605m cash from operations and $231m free cash flow despite higher capex on a new UK wound factory and IT upgrades. Net debt was $3,019m, with an adjusted net-debt-to-EBITDA ratio of 1.8x.
Management cut full-year underlying revenue growth guidance from “around 6%” to “around 4%”, but kept targets for ~8% trading profit growth (around $1.3bn including Integrity Orthopaedics), about $800m free cash flow, and more than 10% adjusted ROIC. A progressive capital-return policy continues, with an interim dividend of 15.6¢ per share (up 4.0%) and a $500m share buyback, of which $216m had been settled by 3 August 2026.
Smith & Nephew plc reported a management share-based compensation event under its Global Share Plan 2020 and Restricted Share Plan 2024. On 12 August 2026, performance share awards granted in 2023 vested, with some shares sold solely to cover tax liabilities.
For Rohit Kashyap, President, Advanced Wound Management and Global Commercial Operations, 23,202 US$0.20 ordinary shares vested at a price of £11.096264 per share, of which 9,163 shares were sold and 14,039 shares were retained. The transaction took place on the London Stock Exchange. The company states that remaining unvested shares under the awards have lapsed.
Smith & Nephew plc reports a major holdings notification from Cevian Capital II G.P. Limited. Cevian, through Cevian Capital II Master Fund L.P. and Cevian Capital II Co-Investment - Series P L.P., now holds 14.214414% of Smith & Nephew’s voting rights, representing 119,179,419 voting rights attached to shares.
The holding via Cevian Capital II Master Fund L.P. is 13.014856% and via Cevian Capital II Co-Investment - Series P L.P. is 1.199558%. This reflects an increase from a previously notified aggregate holding of 14.010786%. The legal owner of the shares is Aurora Nominees Limited, holding on behalf of UBS AG as custodian. Cevian Capital II G.P. Limited states that no new notification threshold has been crossed and that the notification is made for transparency purposes. No voting rights are held through financial instruments.
Smith+Nephew plc reported H1 2026 revenue of $3,097 million, up 4.6% on a reported basis and 2.3% underlying, with Q2 revenue of $1,597 million. Trading profit rose to $566 million and margin to 18.3%, while operating profit was $448 million. Adjusted EPS was 47.7¢ and basic EPS 35.6¢.
Free cash flow was $231 million after higher capital expenditure on a new UK wound factory and IT upgrades, and net debt stood at $3,019 million, a 1.8x adjusted net debt/EBITDA ratio. Sports Medicine & ENT grew strongly, Advanced Wound Management was constrained by US skin-substitute reimbursement changes, and Orthopaedics was broadly flat on an underlying basis.
The company increased its interim dividend 4.0% to 15.6¢ per share and is executing a $500 million share buyback, with $216 million settled by 3 August 2026. Full-year guidance now assumes around 4% revenue growth (from around 6%), but still targets around 8% trading profit growth excluding acquisitions, about $800 million free cash flow and more than 10% ROIC on an adjusted basis.